Form 4: AnaptysBio CFO Dennis Mulroy Reports Stock Transactions

AnaptysBio's CFO, Dennis Mulroy, reports the acquisition and disposal of common stock and derivative securities, including transactions to cover tax obligations and those executed under a pre-arranged 10b5-1 trading plan.

Summary

• Dennis Mulroy, CFO of AnaptysBio, Inc., filed a Form 4 detailing changes in beneficial ownership of company stock.
• On September 14, 2024, Mulroy acquired 6,000 shares of common stock through the vesting of restricted stock units (RSUs).
• On September 16, 2024, Mulroy sold 2,220 shares at $38.93 per share to cover tax withholding obligations related to the RSU vesting.
• Also on September 16, 2024, Mulroy acquired 10,000 shares through the exercise of employee stock options at a price of $20.16.
• Simultaneously, Mulroy sold 10,000 shares at $40.13 per share under a 10b5-1 trading plan.
• Following these transactions, Mulroy directly owns 4,744 shares of common stock.
• Mulroy also holds options to purchase 80,600 shares and an additional 263,040 shares of common stock that vest according to their terms.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reflects routine transactions related to executive compensation and pre-planned stock sales. There's no indication of significant positive or negative developments.

Positives

• The exercise of stock options by the CFO could be interpreted as a positive sign of confidence in the company's future prospects.

Negatives

• The sale of shares to cover tax obligations and under a 10b5-1 plan could be perceived negatively, although these are common practices.

Risks

• The Form 4 filing itself doesn't inherently present risks, but the market's interpretation of the transactions could impact the stock price.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The details of the transactions are specific to the individual's financial planning and company compensation structure.

Comparison to Industry Standards

• Form 4 filings are standard practice across all publicly listed companies, including AnaptysBio's competitors in the biotechnology sector.
• The use of 10b5-1 trading plans is also a common practice among executives to avoid accusations of insider trading, aligning with industry norms.
• The vesting schedules and option grants are typical components of executive compensation packages in biotech companies, similar to those offered by companies like Regeneron or Amgen.

Stakeholder Impact

• The transactions may have a minor impact on shareholders depending on how the market interprets the insider activity.
• Employees may be indirectly affected by the perceived sentiment surrounding the company's stock.

Key Dates